Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H0U4

UPID:
RAB1B_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H0U4; A8K7S1

BACKGROUND:
The small GTPases Rab, including Ras-related protein Rab-1B, are key regulators of vesicle trafficking within cells. Rab-1B specifically plays a role in the development of autophagic vacuoles and regulates transport between the endoplasmic reticulum and Golgi apparatus. It is essential for maintaining the Golgi's compact morphology and promotes recruitment of lipid phosphatase MTMR6, indicating its critical role in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
The exploration of Ras-related protein Rab-1B's function offers a promising avenue for therapeutic intervention. Given its central role in autophagy and vesicle transport, targeting Rab-1B could lead to novel treatments for diseases where these processes are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.